Literature DB >> 11079505

FDG PET imaging in patients with pathologically verified dementia.

J M Hoffman1, K A Welsh-Bohmer, M Hanson, B Crain, C Hulette, N Earl, R E Coleman.   

Abstract

UNLABELLED: The purpose of this study was to confirm with pathologic verification 2 beliefs related to Alzheimer's disease (AD): (a) the long-standing impression that bilateral temporo-parietal hypometabolism, as noted on FDG PET imaging, is the metabolic abnormality associated with Alzheimer's disease (AD) and (b) that the sensitivity, specificity, and diagnostic accuracy of the metabolic pattern of bilateral temporo-parietal hypometabolism allows differentiation between other degenerative causes of dementia.
METHODS: Twenty two individuals (8 women, 14 men) with difficult-to-characterize memory loss or dementia (using standard clinical criteria), and who eventually received pathologic confirmation of diagnosis, were evaluated. FDG PET brain scans were obtained and visually graded by an experienced nuclear medicine physician as to the presence of classic bilateral temporo-parietal hypometabolism as seen in Alzheimer's type dementia. Sensitivity, specificity, positive predictive value, negative predictive value, and diagnostic accuracy of the metabolic pattern of bilateral temporo-parietal hypometabolism were determined using pathologic diagnosis as the gold standard.
RESULTS: The clinical diagnosis of possible or probable AD was determined as the primary cause of dementia in 12 patients. The sensitivity and specificity of the clinical diagnosis for probable AD were 63% and 100%, respectively. The sensitivity and specificity of the clinical diagnosis for possible and probable AD were 75% and 100%, respectively. The sensitivity, specificity, and diagnostic accuracy of bilateral temporo-parietal hypometabolism being associated with AD were 93%, 63%, and 82%, respectively.
CONCLUSION: This study confirms that bilateral temporo-parietal hypometabolism is indeed the classic metabolic abnormality associated with AD. Furthermore, in individuals with dementia whose FDG PET scans indicated a metabolic pattern other than bilateral temporo-parietal hypometabolism, a cause of dementia other than AD should be suspected. These observations may be of clinical importance in differentiating dementia syndromes. The sensitivity, specificity, and diagnostic accuracy of FDG PET are acceptable as tests to be used in the evaluation of dementia and particularly to confirm the clinical suspicion of AD.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11079505

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  95 in total

1.  The dynamics of Alzheimer's disease biomarkers in the Alzheimer's Disease Neuroimaging Initiative cohort.

Authors:  A Caroli; G B Frisoni
Journal:  Neurobiol Aging       Date:  2010-06-11       Impact factor: 4.673

2.  Cognitive reserve modulates functional brain responses during memory tasks: a PET study in healthy young and elderly subjects.

Authors:  Nikolaos Scarmeas; Eric Zarahn; Karen E Anderson; John Hilton; Joseph Flynn; Ronald L Van Heertum; Harold A Sackeim; Yaakov Stern
Journal:  Neuroimage       Date:  2003-07       Impact factor: 6.556

3.  Diagnosis of suspected Alzheimer's disease is improved by automated analysis of regional cerebral blood flow.

Authors:  Bich-Ngoc-Thanh Tang; Satoshi Minoshima; Jean George; Annie Robert; Christian Swine; Patrice Laloux; Thierry Vander Borght
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-07-01       Impact factor: 9.236

4.  Effects of age on the glucose metabolic changes in mild cognitive impairment.

Authors:  Kejal Kantarci; M L Senjem; V J Lowe; H J Wiste; S D Weigand; B J Kemp; A R Frank; M M Shiung; B F Boeve; D S Knopman; R C Petersen; C R Jack
Journal:  AJNR Am J Neuroradiol       Date:  2010-03-18       Impact factor: 3.825

5.  Comparison of gray matter and metabolic reduction in mild Alzheimer's disease using FDG-PET and voxel-based morphometric MR studies.

Authors:  Kazunari Ishii; Hiroki Sasaki; Atsushi K Kono; Naokazu Miyamoto; Tetsuya Fukuda; Etsuro Mori
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-03-31       Impact factor: 9.236

Review 6.  Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases.

Authors:  Michael G Erkkinen; Mee-Ohk Kim; Michael D Geschwind
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-04-02       Impact factor: 10.005

Review 7.  Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD.

Authors:  Lisa Mosconi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-04       Impact factor: 9.236

Review 8.  Emerging biomarkers in cognition.

Authors:  Meredith Wicklund; Ronald C Petersen
Journal:  Clin Geriatr Med       Date:  2013-11       Impact factor: 3.076

9.  Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade.

Authors:  Clifford R Jack; David S Knopman; William J Jagust; Leslie M Shaw; Paul S Aisen; Michael W Weiner; Ronald C Petersen; John Q Trojanowski
Journal:  Lancet Neurol       Date:  2010-01       Impact factor: 44.182

10.  Visual memory tests enhance the identification of amnestic MCI cases at greater risk of Alzheimer's disease.

Authors:  Javier Oltra-Cucarella; Miriam Sánchez-SanSegundo; Darren M Lipnicki; John D Crawford; Richard B Lipton; Mindy J Katz; Andrea R Zammit; Nikolaos Scarmeas; Efthimios Dardiotis; Mary H Kosmidis; Antonio Guaita; Roberta Vaccaro; Ki Woong Kim; Ji Won Han; Nicole A Kochan; Henry Brodaty; José A Pérez-Vicente; Luis Cabello-Rodríguez; Perminder S Sachdev; Rosario Ferrer-Cascales
Journal:  Int Psychogeriatr       Date:  2018-10-25       Impact factor: 3.878

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.